Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065473 | 0.94 | CYP1A2 (0.39) | CYP1A2CYP2C9CYP2C19SIGMAR1ALDH1A1 | |
| SCHEMBL1419719 | 0.88 | ALDH1A1 (0.41) | CYP1A2CYP2C9CYP2C19SIGMAR1ALDH1A1 | |
| SCHEMBL29684479 | 0.88 | ALDH1A1 (0.41) | CYP1A2CYP2C9CYP2C19SIGMAR1ALDH1A1 | |
| SCHEMBL740784 | 0.85 | CD44 (0.38) | CYP1A2CYP2C9CYP2C19ALDH1A1ADRA2B | |
| SCHEMBL15184061 | 0.81 | TSHR (0.39) | ALDH1A1TDP1TAAR1KDM4ETSHR | |
| SCHEMBL31312727 | 0.81 | TSHR (0.38) | CYP1A2CYP2C9CYP2C19SIGMAR1ALDH1A1 | |
| SCHEMBL10694333 | 0.81 | TSHR (0.38) | CYP1A2CYP2C9CYP2C19SIGMAR1ALDH1A1 | |
| SCHEMBL23159850 | 0.80 | ALOX15 (0.47) | SIGMAR1ALDH1A1TDP1TAAR1FDPS | |
| SCHEMBL23159894 | 0.80 | ALOX15 (0.47) | SIGMAR1ALDH1A1TDP1TAAR1FDPS | |
| SCHEMBL6225993 | 0.79 | ALDH1A1 (0.39) | CYP1A2CYP2C9CYP2C19SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-23 | — | — | US | disclosed |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-25 | — | — | US | disclosed |
| WO-2017125530-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-27 | — | — | WO | disclosed |
| US-7842688-B2 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2010-11-30 | — | — | US | disclosed |
| US-7790715-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-09-07 | — | — | US | disclosed |
| US-20090012055-A1 | Organic compounds | HEROLD PETER | 2009-01-08 | — | — | US | disclosed |
| EP-1961752-A2 | Piperidine Compounds | Speedel Experimenta AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070010511-A1 | Organic compounds | NOVARTIS PHARMA AG (CH) | 2007-01-11 | — | — | US | disclosed |
| EP-1670760-A1 | ORGANIC COMPOUNDS | Speedel Experimenta AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005061457-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-07-07 | — | — | WO | disclosed |
| US-4014864-A | POLYESTER FIBERS | CIBA-GEIGY CORPORATION (US) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012055-A1 | Organic compounds | REN, ACE, ACE2 | CYP1A2 51/4885CYP2C9 63/4885CYP2C19 57/4885 |
| US-20070010511-A1 | Organic compounds | REN, ACE, ACE2 | CYP1A2 51/4885CYP2C9 63/4885CYP2C19 57/4885 |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | NFKBIA, IKBKG, IKBKB | CYP1A2 2627/4885CYP2C9 4025/4885CYP2C19 3822/4885 |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | NFKBIA, MAP3K14, IKBKG | CYP1A2 2555/4885CYP2C9 4095/4885CYP2C19 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.